Amgen’s Leukemia Drug Gets Full FDA Approval

Late Tuesday, Amgen (AMGN) announced that the Food and Drug Administration gave its approval to the company’s supplemental biologics license application regarding its leukemia drug, bispecific antibody Blincyto, converting its accelerated approval to a full approval. Getty Images Oppenheimer’s Leah Rush Cann reiterated an Outperform rating and $189 price target on the stock following the report. She writes […]